Core Insights - WuXi Biologics has been awarded "Biologics CDMO of the Year" for the ninth consecutive year at the 2026 CDMO Leadership Awards, highlighting its leadership in the CRDMO sector [1][2] - The company has achieved excellence in multiple categories, including "Best Scaling Support," "Best Analytical Services," "Best Overall Staff," and "Best Project Management" [1][2] Company Achievements - As of the end of 2025, WuXi Biologics has 945 integrated projects, with over 50% being complex modalities such as bi-/multi-specific antibodies and ADCs [2] - The timelines for WuXi Biologics from DNA to IND and from IND to BLA have been reduced to 6 months and 15 months, respectively, compared to industry averages of 10-12 months and 24-36 months [2] - The company has a 100% success rate in PPQ campaigns and has delivered over 350 large-scale batches (6,000 L – 16,000 L per batch) since 2017 [4] Manufacturing and Quality - WuXi Biologics operates 15 GMP-certified drug substance and drug product facilities globally, with a 100% success rate in GMP inspections and 136 facility license approvals [4] - The company has passed 46 regulatory inspections, including 22 by the FDA and EMA, and holds a 100% pass rate for FDA Pre-License Inspection [4] Technological Innovations - WuXi Biologics is advancing digital innovation in biologics research and manufacturing, achieving approximately 40% productivity gains through digital manufacturing solutions [5] - The launch of the digital twin platform PatroLab™ aims to enhance process performance and minimize risks in biologics manufacturing [6] Sustainability Commitment - The company emphasizes sustainability as a cornerstone of long-term growth, driving green technology innovations and promoting responsible practices across the value chain [9]

Core Insights - WuXi Biologics has achieved a historic record by winning six awards and two individual leadership awards at the 2026 Asia-Pacific Biopharma Excellence Awards, highlighting its leadership in bioprocessing, manufacturing, and digital innovation [1] Group 1: Awards and Recognition - The company won in categories such as Excellence in Bioprocessing Automation & Digitalization, Bioprocessing Facility of the Year, and Best Contract Development & Manufacturing Organization Award [1] - Dr. Sherry Gu was named CTO of the Year, and Dr. Jeremy Guo received the award for Head of Fill-Finish & Formulation of the Year, recognizing their contributions to biologics development and manufacturing [1] Group 2: Business Operations and Achievements - WuXi Biologics operates 945 integrated projects, with nearly 50% involving bi- and multi-specific antibodies and ADCs, making it one of the largest portfolios of complex biologics globally [1] - The company has achieved a 100% success rate in PPQ campaigns and delivered over 350 large-scale batches (6,000 L – 16,000 L per batch) since 2017 [1] - WuXi Biologics has passed 46 regulatory inspections, including 22 by the FDA and EMA, maintaining a 100% pass rate for FDA Pre-License Inspection [1] Group 3: Technological Innovations - The company launched WuXia™ TrueSite, achieving average mAb titers over 8.0 g/L, and advanced its high-dose delivery technologies, enabling protein concentrations of up to 230 mg/mL [1] - WuXi Biologics has integrated digital innovation across R&D and manufacturing, achieving approximately 40% productivity gains and a 20% improvement in efficiency through advanced planning systems [1] Group 4: Sustainability and ESG Commitment - WuXi Biologics emphasizes sustainability as a cornerstone of long-term growth, driving green technology innovations and achieving excellence in Environment, Social, and Governance (ESG) practices [2]

Core Insights - WuXi Biologics has launched PatroLab, a digital twin platform aimed at transforming bioprocess development and manufacturing through advanced analytics and predictive modeling [1][2] Group 1: PatroLab Overview - PatroLab integrates real-time process monitoring, Raman-based Process Analytical Technology (PAT), and predictive in-silico modeling to enhance process performance and minimize risks [1][2] - The platform aims to accelerate decision-making and shorten development timelines, ensuring high-quality biologics manufacturing [1][2] Group 2: Technological Innovations - The advanced Raman PAT system allows for real-time, non-invasive monitoring of over 40 key process performance and product quality attributes, moving away from traditional static testing [3] - PatroLab increases data density per batch by nearly 1,000 times compared to traditional methods, facilitating the application of Quality by Design (QbD) principles [4] Group 3: Process Improvement and Risk Management - The platform supports rapid chemical characterization of raw materials, enabling proactive interventions to reduce batch variations and ensure product consistency [5] - By utilizing data-driven and mechanistic modeling, PatroLab creates virtual bioprocess replicas, allowing for predictive decision-making and "what-if" scenario analysis [6][7] Group 4: Manufacturing Efficiency - PatroLab reduces process deviations and batch rejection rates through end-to-end monitoring aligned with critical quality attributes, improving overall success rates [9] - The platform enables dynamic, model-predictive control and automated strategies, enhancing efficiency and reliability in biomanufacturing [10] Group 5: Collaboration and Knowledge Management - PatroLab is integrated into WuXi Biologics' digital ecosystem, facilitating real-time data sharing and collaboration across teams for bioprocess development [11]